Literature DB >> 22734907

A novel EGR2 mutation within a family with a mild demyelinating form of Charcot-Marie-Tooth disease.

Kensuke Shiga1, Yuichi Noto, Ikuko Mizuta, Akihiro Hashiguchi, Hiroshi Takashima, Masanori Nakagawa.   

Abstract

Mutations of the early growth response 2 (EGR2) gene have been reported in a variety of severe demyelinating neuropathies such as autosomal recessive congenital hypomyelinating neuropathy, autosomal dominant child-onset Dejerine-Sottas neuropathy, and autosomal dominant adult-onset Charcot-Marie-Tooth disease (CMT). Here, we report on a heterozygous mutation in EGR2 (c.1160C>A), which results in threonine at position 387 being changed to asparagine, in a family with a mild demyelinating form of adult-onset CMT. Of note, both the proband and her asymptomatic son exhibited neither pes cavus nor champagne-bottle leg atrophy, suggesting that the heterozygous T387N mutation may result in a relatively mild phenotype of demyelinating CMT.
© 2012 Peripheral Nerve Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22734907     DOI: 10.1111/j.1529-8027.2012.00403.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  3 in total

Review 1.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

2.  Sequence variations of the EGR4 gene in Korean men with spermatogenesis impairment.

Authors:  Se Ra Sung; Seung Hun Song; Kyung Min Kang; Ji Eun Park; Yeo Jung Nam; Yun-Jeong Shin; Dong Hyun Cha; Ju Tae Seo; Tae Ki Yoon; Sung Han Shim
Journal:  BMC Med Genet       Date:  2017-05-02       Impact factor: 2.103

3.  A de novo EGR2 variant, c.1232A > G p.Asp411Gly, causes severe early-onset Charcot-Marie-Tooth Neuropathy Type 3 (Dejerine-Sottas Neuropathy).

Authors:  Bianca R Grosz; Natasha B Golovchenko; Melina Ellis; Kishore Kumar; Garth A Nicholson; Anthony Antonellis; Marina L Kennerson
Journal:  Sci Rep       Date:  2019-12-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.